Phaseline

Companies › Valenta Pharm JSC

Valenta Pharm JSC: clinical trials, targets and expected readouts

8 active drug programs in 12 registered trials: 6 Phase 1, 3 Phase 2, 2 Phase 4, 1 Phase 3; Respiratory, Gastroenterology, Infectious disease, Psychiatry; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vespireit
5-HT1A receptor agonist
HTR1APhase 4VertigoDec 2026
Ranquilon–Phase 4AnxietyDec 2027
4-MUST (trimebutine 4-methylumbelliferyl sulfate)
Trimebutine derivative; prokinetic agent acting as TRPV1 agonist and 5-HT4 receptor agonis
TRPV1, HTR4Phase 3Chronic CholecystitisDec 2026
Grammidin with anesthetic
Local anesthetic and antimicrobial topical spray
–Phase 2Pharyngitis AcuteDec 2026
Ingavirin Forte
Combination of imidazolylethanamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclope
–Phase 2InfluenzaDec 2027
Benoxinate
Sodium channel alpha subunit blocker
Ion channelsPhase 1PharyngitisDec 2026
Grammidin, a metered dose topical spray
Antimicrobial combination containing gramicidin S and cetylpyridinium chloride
–Phase 1PharyngitisDec 2026
Trimedat® 76.95 mg orally disintegrating tablets
Trimebutine maleate - prokinetic agent
–Phase 1Irritable Bowel SyndromeDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06857890BenoxinatePhase 1PharyngitisRespiratoryDec 2026
NCT06859281Grammidin, a metered dose topical sprayPhase 1PharyngitisRespiratoryDec 2026
NCT07421011Trimedat® 76.95 mg orally disintegrating tabletsPhase 1Irritable Bowel SyndromeGastroenterologyDec 2026
NCT068429664-MUST (trimebutine 4-methylumbelliferyl sulfate)Phase 2Chronic CholecystitisGastroenterologyDec 2026
NCT06843018Grammidin with anestheticPhase 2Pharyngitis AcuteRespiratoryDec 2026
NCT06321341VespireitPhase 4VertigoNeurologyDec 2026
NCT075949774-MUST (trimebutine 4-methylumbelliferyl sulfate)Phase 1Chronic CholecystitisGastroenterologyJun 2027
NCT07420985Ingavirin FortePhase 2InfluenzaInfectious diseaseDec 2027
NCT07645534Ingavirin FortePhase 1InfluenzaInfectious diseaseDec 2027
NCT07645534Ingavirin FortePhase 1InfluenzaInfectious diseaseDec 2027
NCT075950034-MUST (trimebutine 4-methylumbelliferyl sulfate)Phase 3Chronic CholecystitisGastroenterologyDec 2027
NCT06843044RanquilonPhase 4AnxietyPsychiatryDec 2027

Targets

TRPV1 (1) HTR4 (1) Ion channels (1) HTR1A (1)

Companies with the same targets

RDC Clinical Xenon Pharmaceuticals Praxis Precision Medicines Otsuka Heron Therapeutics HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed

Companies built like this

Shionogi Chiesi Farmaceutici Vertex Pharmaceuticals Teva Branded Pharmaceutical Products R&D Beijing Continent Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.